AGIOS PHARMACEUTICALS, INC. Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount of $124.30 million for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-07.
Discontinued › Notes › Revenue Recognition and Deferred Revenue
us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount · last filed 2014-08-07
- AGIOS PHARMACEUTICALS, INC. revenue recognition, multiple-deliverable arrangements, determination of selling price, amount for the quarter ending 2014-03-31 was $124.30M.
- AGIOS PHARMACEUTICALS, INC. revenue recognition, multiple-deliverable arrangements, determination of selling price, amount for fiscal 2013 was $124.30M.
| Period end | Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount 3 month | Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount 6 month | Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount 9 month | Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount 12 month |
|---|---|---|---|---|
| 2014-06-30 | $124.30M 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $124.30M 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $124.30M 10-K · filed 2014-03-18 | |||
| 2013-09-30 | $124.30M 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |